First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.

MLA

Huang, Xiaoting, et al. “First-Line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive Advanced Breast Cancer: A Cost-Effectiveness Analysis.” Clinical Breast Cancer, vol. 21, no. 4, Aug. 2021, pp. e479–88. EBSCOhost, https://doi.org/10.1016/j.clbc.2021.01.019.

APA

Huang, X., Lin, S., Rao, X., Zeng, D., Wang, H., Weng, X., & Huang, P. (2021). First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis. Clinical Breast Cancer, 21(4), e479–e488. https://doi.org/10.1016/j.clbc.2021.01.019

Chicago

Huang, Xiaoting, Shen Lin, Xin Rao, Dayong Zeng, Hang Wang, Xiuhua Weng, and Pinfang Huang. 2021. “First-Line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive Advanced Breast Cancer: A Cost-Effectiveness Analysis.” Clinical Breast Cancer 21 (4): e479–88. doi:10.1016/j.clbc.2021.01.019.